tirzepatide and propranolol ⚠️ New Sensory Side Effects Reported with GLP-1 Drugs, Medications like Semaglutide are widely used for Type 2 diabetes and weight loss, but recent reports suggest possible sensory Have questions about Zepbound (tirzepatide)

It is also worth noting that recently (May 2019) the EMA has granted conditional approval for the use of a novel agent effectively lowering TG concentration in monogenic chylomicronaemia [215]

Patients should be reviewed at 36 month intervals to assess treatment response, tolerability, and ongoing appropriateness of therapy

Fielding PE

General PA criteria include: BMI threshold: BMI 30 (obesity), or BMI 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, or cardiovascular disease) Documentation of medical necessity: Clinical notes confirming obesity diagnosis, comorbidities, and treatment rationale from a licensed provider Prior lifestyle program participation: Many plans require documentation of participation in a structured diet and exercise program for a defined period (typically 36 months) before GLP-1 medications are authorized Non-diabetic indication: For Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide weight loss dose), the weight management indication must be documented separately from diabetes management Step therapy: Some Cigna plans may require an oral agent (such as phentermine or Contrave) trial before authorizing higher-cost GLP-1 medications Ongoing authorization: GLP-1 PA approvals are typically renewable annually and may require documentation of 5% body weight reduction to continue coverage Klarity Healths clinical team may assist with the prior authorization process